SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation seeks to determine whether Kymera Therapeutics's directors breached their fiduciary duties...
Covered in this story
What has happened since
- Kymera Therapeutics Inc is down 2.4% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Kymera Therapeutics Inc
- Raymond James: $109 → $140 by Oct 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $KYMR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kymera Therapeutics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.